Hadasit Bio-Holdings Ltd. (HBL), a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by Hadassah University Hospital, in Jerusalem, Israel,  announced that its portfolio company, KAHR Medical Ltd. has received US patent approval (US Patent No. 8329657) for its lead product, KAHR-101.  

This patent approval follows other patents already received in the US, Europe, Japan and Israel, protecting different combinations of KAHR's 'Signal Converting Proteins (SCPs)', which are bi-functional chimeric proteins with synergistic effects that improve the efficiency of pharmaceutical treatments. The newly issued patent protects one of KAHR's products in development, KAHR-101, which has been shown to be effective in the treatment of various cancers, arthritis and multiple sclerosis in animal models.

"KAHR Medical develops ground-breaking products and we are constantly working to strengthen the company's intellectual property. The company uses a novel technology by which two therapeutic pathways can be simultaneously stimulated by a single protein drug in a synergistic manner, optimizing the care provided to patients. The completion of a recent fundraising round a few months ago will allow for further development and advancement of KAHR's drugs. We believe that in the coming year our portfolio companies will continue to present considerable clinical and business developments increasing their value as well as ours," said Ophir Shahaf , CEO, Hadasit Bio-Holdings.